# Osimertinib for Advanced EGFR-positive NSCLC Patients

> **NCT05037331** · — · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 58 (estimated)

## Conditions studied

- EGFR Positive Non-small Cell Lung Cancer
- Non Small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05037331
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-22
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05037331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05037331, "Osimertinib for Advanced EGFR-positive NSCLC Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05037331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*